| Literature DB >> 28652020 |
Andrey Komissarov1, Artem Fadeev2, Anna Kosheleva2, Kseniya Sintsova2, Mikhail Grudinin2.
Abstract
Influenza and other acute respiratory infections are of great concern for public health, causing excessive morbidity and mortality throughout the world. Influenza virus A(H2N2), which caused a pandemic of so called "Asian flu" in 1957 was expelled from the human population by the new pandemic virus subtype H3N2 in 1968, however, influenza A(H2) viruses continue to circulate in wild birds and poultry. The lack of immunity in human population and the continued circulation of influenza A(H2) among animals makes emergence of a new pandemic virus possible. One of the basic techniques of molecular diagnostics of infectious diseases is the realtime polymerase chain reaction (PCR). The aim of this work was to design oligonucleotide primers and probes for the rapid detection of influenza A virus subtype H2 by realtime reverse transcription - polymerase chain reaction (rRT-PCR). Analysis of 539 sequences of influenza A(H2N2) virus hemagglutinin gene from GISAID EpiFlu database revealed conservative regions suitable for use as binding sites for primers and probes. 191 probes were designed and 2 sets of primers and probes (H2-1 and H2-2) were selected for further experimental evaluation. Detection limit of RT-PCR system was 50 copies of DNA per 25 μl reaction when 10-fold dilutions of pCI-neo-H2 plasmid used as template. Analytical specificity of selected sets of primers and probes were tested on wide range of influenza strains and non-influenza respiratory viruses. H2-2 set found to have insufficient specificity detecting seasonal influenza A(H1N1) viruses and was excluded from further analysis. Analytical sensitivity was further tested on vaccine strain A/17/California/66/395 (H2N2) and A/Japan/305/1957 (H2N2), limit of detection for primers-probe set H2-1 was 3.2 (CI95%: 3.07-3.48) lg EID50/ml. Designed primers and probes for the realtime RT-PCR universal detection of influenza A(H2) viruses could be used in clinical trials of vaccines against influenza A(H2) and screening for H2 in cases of unsubtypeable influenza A in humans.Entities:
Keywords: H2; Influenza A; Realtime PCR; TaqMan
Mesh:
Year: 2017 PMID: 28652020 PMCID: PMC7126497 DOI: 10.1016/j.mcp.2017.06.005
Source DB: PubMed Journal: Mol Cell Probes ISSN: 0890-8508 Impact factor: 2.365
Primers and probes for identification of influenza A(H2) viruses.
| Primer/probe | Sequence (5′-3′) | Length | Tm | Binding site |
|---|---|---|---|---|
| H2-P1 | 23 | 67,37 | 409–431 | |
| H2-F1 | AAGATTCTGCCCAAAGAT | 18 | 57,80 | 388–405 |
| H2-R1 | TCCGCTCGTATTGTTGTA | 18 | 60,05 | 532–549 |
| H2-P2 | 23 | 66,09 | 1354–1332 | |
| H2-F2 | CTTCTAGTCCTGATGGAA | 18 | 56,5 | 1300–1317 |
| H2-R2 | GCATTCTGACTTTTTCATAC | 20 | 56,72 | 1368–1387 |
Tm is calculated using Beacon Designer (oligo concentration: 200 nM, monovalent ion concentration: 50 mM, free magnesium concentration: 3 mM).
Fig. 1Shannon entropy (H) distribution across H2 hemagglutinin sequence and web-logos for two selected probe binding sites in local H-value minima.
Fig. 2Standard curves to evaluate efficiency of RT-PCR on pCI-neo-H2 plasmid (A) and A/17/California/66/395 virus (B) using H2-1 and H2-2 primers/probes sets.
Fig. 3(A) Determination of limit of detection of rRT-PCR H2-1 assay. (B) Number of positives versus the virus titre of influenza A/Japan/305/1957 (H2N2) virus for RT-PCR H2-1 assay and a regression curve determined by probit regression analysis.
Fig. 4(A) Comparison of RT-PCR H2-1 assay performance on influenza A/Japan/305/1957 (H2N2) virus dilutions (PBS) and artificial human specimens spiked with A/Japan/305/1957 (H2N2) virus (SWAB). NS – no significance, * – P < 0.0001. (B) Agarose electrophoresis of rRT-PCR amplification products of LAIV A/17/California/66/395 (H2N2) using H2-1 and H2-2 primer sets.
Analytical specificity of rRT-PCR assay.
| Virus/Sample | Subtype | H2 rRT-PCR assay | CDC rRT-PCR assay | ||||||
|---|---|---|---|---|---|---|---|---|---|
| H2-1 | H2-2 | InfA | H1 | H1pdm09 | H3 | H5 | H7 | ||
| Influenza viruses | |||||||||
| A/Japan/305/1957 | H2N2 | + | + | + | NT | NT | NT | NT | NT |
| A/17/California/66/395 | H2N2 | + | + | + | NT | NT | NT | NT | NT |
| Pooled influenza positive control (PIPC) | InfB, H1N1pdm09, H1N1, H3N2 | – | + | + | + | + | + | – | – |
| A/Nizhniy Novgorod/RII01/2013 | H1N1pdm09 | – | – | + | – | + | – | – | – |
| A/Saint-Petersburg/RII06/2013 | H3N2 | – | – | + | – | – | + | – | – |
| A/Saint-Petersburg/RII66/2009 | H1N1 | – | ± | + | + | – | – | – | – |
| A/Vietnam/1203/2004 | H5N1 | – | – | + | – | – | – | + | – |
| A/Anhui/1/2013 | H7N9 | – | – | + | – | – | – | – | + |
| A/seal/Caspian sea/01/2000 | H7N7 | – | – | + | – | – | – | – | + |
| A/herring gull/Atyrau/2186/2007 | H11N2 | – | – | + | – | – | – | – | – |
| A/Saint-Petersburg/38/2008 | H1N1 | – | NT | + | + | – | – | – | – |
| A/Saint-Petersburg/95/2008 | H1N1 | – | NT | + | + | – | – | – | – |
| A/Saint-Petersburg/52/2001 | H1N1 | – | NT | + | + | – | – | – | – |
| C/Taylor/47 | InfC | – | NT | – | – | – | – | – | – |
| Non-influenza respiratory viruses | |||||||||
| hRSVA strain A2 | hRSVA | – | NT | – | – | – | – | – | – |
| hRSVB strain 9320 | hRSVB | – | NT | – | – | – | – | – | – |
| HPIV2/Saint-Petersburg/10568/2011 | hPIV2 | – | NT | – | – | – | – | – | – |
| HPIV3/Saint-Petersburg/123/2014 | hPIV3 | – | NT | – | – | – | – | – | – |
| Human adenovirus serotype 1 (type C) | – | NT | – | – | – | – | – | – | |
NT – not tested.
Component of CDC real-time RT-PCR positive controls.